Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)Jean‐Jacques Kiladjian, Bruno Cassinat, Juliette Soret et al.|Blood|2022Cited by 21